272,987 results match your criteria Myocardial Infarction

Macronutrient quality index and cardiovascular disease risk in the Seguimiento Universidad de Navarra (SUN) cohort.

Eur J Nutr 2022 May 22. Epub 2022 May 22.

School of Medicine, Department of Preventive Medicine and Public Health, University of Navarra, Campus Universitario, 31080, Pamplona, Spain.

Purpose: To assess the association between a multi-dimensional Macronutrient Quality Index (MQI) and the risk of cardiovascular disease (CVD) in a Mediterranean cohort.

Methods: Prospective analyses among 18,418 participants (mean age 36 years, 60.8% women) of the Seguimiento Universidad de Navarra (SUN) cohort. Read More

View Article and Full-Text PDF

Serum uric acid in patients with ST-segment elevation myocardial infarction: An innocent bystander or leading actor?

Nutr Metab Cardiovasc Dis 2022 Apr 4. Epub 2022 Apr 4.

Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address:

Elevated serum uric acid (SUA) levels have been associated with several cardiovascular risk factors and the progression of coronary artery disease. In the setting of acute myocardial infarction, increasing evidence suggests that high SUA levels could be related to adverse outcomes. Interestingly elevated SUA levels have been linked to endothelial dysfunction, inflammation and oxidative stress. Read More

View Article and Full-Text PDF

Timing of Repair in Postinfarction Ventricular Septal Defect.

Am J Cardiol 2022 May 18. Epub 2022 May 18.

Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio. Electronic address:

The optimal timing of postinfarction ventricular septal defect (PI-VSD) repair is subject to debate. Patients with ventricular septal defect (VSD) and ST-elevation myocardial infarction (STEMI) were queried using appropriate International Classification of Diseases, Ninth and Tenth Revision Clinical Modification codes from the National Inpatient Sample (2003 to 2018). VSD repair was identified using appropriate International Classification of Diseases, Ninth and Tenth Revision Procedure Coding System codes. Read More

View Article and Full-Text PDF

Necroptosis in heart disease: Molecular mechanisms and therapeutic implications.

J Mol Cell Cardiol 2022 May 18. Epub 2022 May 18.

Department of Physiology and Biophysics, University of Washington, Seattle, WA, USA. Electronic address:

Cell death is a crucial event underlying cardiac ischemic injury, pathological remodeling, and heart failure. Unlike apoptosis, necrosis had long been regarded as a passive and unregulated process. However, recent studies demonstrate that a significant subset of necrotic cell death is actively mediated through regulated pathways - a process known as "regulated necrosis". Read More

View Article and Full-Text PDF

Outcomes and prognostic factors of patients treated for in-stent restenosis: a retrospective single-center experience.

Egypt Heart J 2022 May 21;74(1):42. Epub 2022 May 21.

Department of Cardiology, Farhat Hached University Hospital Center, Sousse, Tunisia.

Background: The incidence of in-stent restenosis (ISR) remains relatively common despite the use of drug-eluting stents. Outcomes and prognostic factors following ISR revascularization are still being investigated. We aimed to describe the outcomes following different ISR treatment strategies in order to identify prognostic factors associated with worse outcomes. Read More

View Article and Full-Text PDF

Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes.

Cardiovasc Diabetol 2022 May 20;21(1):80. Epub 2022 May 20.

Fuwai Hospital, Chinese Academy of Medical Sciences, 12 Langshan Rd, Shenzhen, 518000, China.

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be predictive of cardiovascular outcomes in stable coronary artery disease with diabetes. We aimed to assess the relationship between PCSK9 and major adverse cardiovascular events (MACEs) in ST-segment elevation myocardial infarction (STEMI) patients with or without diabetes, as well as the relationships between PCSK9 and metabolism, inflammation and platelet activation markers.

Methods: A total of 1027 patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and without prior lipid-lowering therapy were consecutively enrolled and the baseline plasma PCSK9 levels were determined by ELISA. Read More

View Article and Full-Text PDF

The application of myocardial contrast echocardiography in assessing microcirculation perfusion in patients with acute myocardial infarction after PCI.

BMC Cardiovasc Disord 2022 May 20;22(1):233. Epub 2022 May 20.

Department of Radiology, Tongjiang People's Hospital, Tongjiang City, 156400, China.

Background: To evaluate the myocardial microcirculation perfusion of patients with acute ST-segment elevation myocardial infarction (STEMI) with a different index of microcirculatory resistance (IMR) after percutaneous coronary intervention (PCI) by myocardial contrast echocardiography (MCE) and analyse the value of MCE in predicting myocardial perfusion after PCI.

Methods: Fifty-six patients with acute STEMI who underwent an emergency PCI were selected from October 2018 to October 2019 in our hospital. According to the IMR values measured during PCI treatment, the patients were divided into three groups. Read More

View Article and Full-Text PDF

Impacts of two behavior change interventions on determinants of medication adherence: process evaluation applying the health action process approach and habit theory alongside a randomized controlled trial.

J Behav Med 2022 May 20. Epub 2022 May 20.

Centre for Implementation Research, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus, 501 Smyth Road, K1H 8L6, Ottawa, Ontario, Canada.

Investigating the mechanisms of behavior change interventions provides a more fulsome understanding of how and why interventions work (or don't work). We assessed mechanisms of two interventions (mailouts alone, and mailouts plus telephone support, informed by the Health Action Process Approach (HAPA) and Habit Theory), designed to increase medication adherence after myocardial infarction. We conducted a process evaluation alongside a pragmatic trial. Read More

View Article and Full-Text PDF

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.

Am J Cardiovasc Drugs 2022 May 21. Epub 2022 May 21.

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Background: Inclisiran is a novel, cholesterol-lowering therapy, with a long duration of effect, administered every 6 months (subcutaneously by a healthcare professional). In the ORION-10 trial in US patients with atherosclerotic cardiovascular disease (ASCVD) in addition to maximum tolerated statins, with or without ezetimibe, inclisiran demonstrated statistically significant reductions in low-density lipoprotein cholesterol (LDL-C) of up to 51%. This is the first peer-reviewed publication to investigate the price at which inclisiran is cost effective in the US. Read More

View Article and Full-Text PDF

Murine cardiac fibrosis localization using adaptive Bayesian cardiac strain imaging in vivo.

Sci Rep 2022 May 20;12(1):8522. Epub 2022 May 20.

Medical Physics, University of Wisconsin (UW)-Madison, Madison, USA.

An adaptive Bayesian regularized cardiac strain imaging (ABR-CSI) algorithm for in vivo murine myocardial function assessment is presented. We report on 31 BALB/CJ mice (n = 17 females, n = 14 males), randomly stratified into three surgical groups: myocardial infarction (MI, n = 10), ischemia-reperfusion (IR, n = 13) and control (sham, n = 8) imaged pre-surgery (baseline- BL), and 1, 2, 7 and 14 days post-surgery using a high frequency ultrasound imaging system (Vevo 2100). End-systole (ES) radial and longitudinal strain images were used to generate cardiac fibrosis maps using binary thresholding. Read More

View Article and Full-Text PDF

Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction.

Sci Rep 2022 May 20;12(1):8574. Epub 2022 May 20.

Université de Lorraine, Centre d'Investigation Clinique-Plurithématique Inserm CIC-P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for cardiovascular (CV) events including HF hospitalization, stroke, myocardial infarction (MI) and sudden cardiac death (SCD). The present study evaluated associations of proteomic biomarkers with CV outcome in patients with CAD and HF with reduced ejection fraction (HFrEF), shortly after a worsening HF episode. We performed a case-control study within the COMMANDER HF international, double-blind, randomized placebo-controlled trial investigating the effects of the factor-Xa inhibitor rivaroxaban. Read More

View Article and Full-Text PDF

Effect of Short-Term Exposure to Fine Particulate Matter and Particulate Matter Pollutants on Triggering Acute Myocardial Infarction and Acute Heart Failure.

Am J Cardiol 2022 May 17. Epub 2022 May 17.

Graduate Institute of Injury Prevention and Control, College of Public Health, Taipei Medical University, Taipei, Taiwan. Electronic address:

Long-term exposure to high concentrations of air pollution is known to lead to increased cardiovascular disease, but it remains unclear whether short-term exposure increases the incidence of acute myocardial infarction (AMI) and acute heart failure (AHF). A time-stratified case-crossover design was used, including data from the 2-year period (January 1, 2017 to December 31, 2018), from the National Health Insurance Academic Research Database of Taiwan. Air pollution data were obtained from the Air Quality Monitoring Station of the Environmental Protection Agency of the Executive Yuan. Read More

View Article and Full-Text PDF

Statin Administration for ST-Elevation Myocardial Infarction During Rotor Wing Transport.

Air Med J 2022 May-Jun;41(3):326-327. Epub 2022 Mar 9.

Department of Emergency Medicine, University of Cincinnati College of Medicine; UC Health Air Care & Mobile Care, Cincinnati, Ohio.

Objective: The aim of this study was to evaluate the feasibility of statin administration by a critical care transport medicine (CCTM) team during rotor wing transport for ST-elevation myocardial infarction patients to a percutaneous intervention-capable center.

Methods: We conducted a retrospective study at a single CCTM program after an intervention focused on statin administration for ST-elevation myocardial infarction that included a formulary change and a single brief educational presentation to flight physicians. A comparison group of flight nurse practitioners underwent training after the study period and were used as a control. Read More

View Article and Full-Text PDF

Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial.

Am Heart J 2022 May 17. Epub 2022 May 17.

Baylor Scott and White Research Institute, Dallas Tx; Department of Medicine, University of Mississippi, Jackson, MS. Electronic address:

Background: Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose cotransporter-2 inhibitors have been proven to improve outcomes in patients with HF with reduced ejection fraction, and, in the case of empagliflozin, in HF with preserved ejection fraction even without diabetes, but their efficacy and safety in the post-MI population has not yet been evaluated.

Methods: The EMPACT-MI trial will evaluate the safety and efficacy of empagliflozin compared with placebo in patients hospitalized for MI with or at high risk of new onset HF, in addition to standard care. Read More

View Article and Full-Text PDF

Prediabetes versus type 2 diabetes in patients with acute myocardial infarction and current smoking.

Am J Med Sci 2022 May 17. Epub 2022 May 17.

Division of Cardiology Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Background: Smoking is linked with increased risk of cardiovascular events among diabetic patients. Prediabetes is associated with increased risk for microvascular and macrovascular complications. We compared the 2-year clinical outcomes of current smoking between prediabetic and type 2 diabetes mellitus (T2DM) patients with acute myocardial infarction (AMI) after newer-generation drug-eluting stent (DES) implantation. Read More

View Article and Full-Text PDF

Electrospun electroconductive constructs of aligned fibers for cardiac tissue engineering.

Nanomedicine 2022 May 17:102567. Epub 2022 May 17.

Center for Bioelectronics, Biosensors and Biochips (C3B®), Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA; Department of Electrical and Computer Engineering, Texas A&M University, College Station, TX, USA; Department of Cardiovascular Sciences, Houston Methodist Institute for Academic Medicine and Houston Methodist Research Institute, Houston, TX, USA; ABTECH Scientific, Inc., Biotechnology Research Park, 800 East Leigh Street, Richmond, VA, USA. Electronic address:

Myocardial infarction remains the leading cause of death in the western world. Since the heart has limited regenerative capabilities, several cardiac tissue engineering (CTE) strategies have been proposed to repair the damaged myocardium. A novel electrospun construct with aligned and electroconductive fibers combining gelatin, poly(lactic-co-glycolic) acid and polypyrrole that may serve as a cardiac patch is presented. Read More

View Article and Full-Text PDF

Erratum. Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes. Diabetes Care 2020;43:460-467.

Diabetes Care 2022 May 20. Epub 2022 May 20.

During the conduction of a recent analysis, an error in the coding of the rule-in path of the ESC 0/3-h algorithm in the main database was discovered. This coding error affected the diagnostic measures for the positive predictive value and the specificity to detect acute myocardial infarction. In summary, the coding error resulted in an incorrect high relative increase of troponin comparing the baseline and 3-h value, while all other analyses were not affected. Read More

View Article and Full-Text PDF

Reperfusion therapy for ST-elevation myocardial infarction complicated by cardiogenic shock: the European Society of Cardiology EurObservational programme acute cardiovascular care-European association of PCI ST-elevation myocardial infarction registry.

Eur Heart J Acute Cardiovasc Care 2022 May 20. Epub 2022 May 20.

Hospital Rudolfstiftung, Vienna, Austria.

Aims: To determine the current state of the use of reperfusion and adjunctive therapies and in-hospital outcomes in European Society of Cardiology (ESC) member and affiliated countries for patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS).

Methods And Results: ESC EurObservational Research Programme prospective international cohort study of admissions with STEMI within 24 h of symptom onset (196 centres; 26 ESC member and 3 affiliated countries). Of 11 462 patients enrolled, 448 (3. Read More

View Article and Full-Text PDF

An update on the functional roles of long non‑coding RNAs in ischemic injury (Review).

Int J Mol Med 2022 Jul 20;50(1). Epub 2022 May 20.

Affiliated Eye Hospital of Nanchang University, Jiangxi Research Institute of Ophthalmology and Visual Science, Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, Jiangxi 330006, P.R. China.

Ischemic injuries result from ischemia and hypoxia in cells. Tissues and organs receive an insufficient supply of nutrients and accumulate metabolic waste, which leads to the development of inflammation, fibrosis and a series of other issues. Ischemic injuries in the brain, heart, kidneys, lungs and other organs can cause severe adverse effects. Read More

View Article and Full-Text PDF

Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation.

ESC Heart Fail 2022 May 20. Epub 2022 May 20.

Division of Cardiology, Medical University of Vienna, Vienna, Austria.

Aims: We aim to explore the relationship of heart failure (HF) and diabetes with cardiovascular (CV) death or hospitalization for HF (HHF) and to study the clinical utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in an unselected patient population with atrial fibrillation (AF).

Methods And Results: Patients with AF admitted to a tertiary academic center between January 2005 and July 2019 were identified through a search of electronic health records. We used Cox regression models adjusted for age, sex, estimated glomerular filtration rate, diabetes, HF, body mass index, prior myocardial infarction, coronary artery disease, hypertension, smoking, C-reactive protein, and low-density lipoprotein cholesterol. Read More

View Article and Full-Text PDF

Is the Hospital Value-Based Purchasing Program Associated with Reduced Hospital Readmissions?

J Multidiscip Healthc 2022 12;15:1089-1099. Epub 2022 May 12.

Colorado Hospital Association, Greenwood Village, CO, USA.

Introduction: Hospital readmissions have been associated with adverse outcomes and elevated financial costs to patients, families, and hospitals across the United States. Historically, nearly 20% of all Medicare discharges had a readmission within 30 days. In an effort to address this issue, the Affordable Care Act (ACA) established the Hospital Readmission Reduction Program (HRRP) in 2012 to positively influence readmissions associated with acute myocardial infarction, chronic obstructive pulmonary disease, heart failure, pneumonia, coronary artery bypass graft surgery, and total hip and/or knee arthroplasty. Read More

View Article and Full-Text PDF

The ceRNA Crosstalk between mRNAs and lncRNAs in Diabetes Myocardial Infarction.

Dis Markers 2022 9;2022:4283534. Epub 2022 May 9.

Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing 100029, China.

Competitive endogenous RNA regulation suggests an intricate network of all transcriptional RNAs that have the function of repressing miRNA function and regulating mRNA expression. Today, the specific ceRNA regulatory mechanisms of lncRNA-miRNA-mRNA in patients who have diabetes mellitus (DM) and myocardial infarction (MI) are still unknown. Two data sets, GSE34198 and GSE112690, were rooted in the Gene Expression Omnibus database to search for changes of lncRNA, miRNA, and mRNA in MI patients with diabetes. Read More

View Article and Full-Text PDF

CircERBB2IP promotes post-infarction revascularization via the miR-145a-5p/Smad5 axis.

Mol Ther Nucleic Acids 2022 Jun 20;28:573-586. Epub 2022 Apr 20.

Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.

Myocardial infarction is one of the leading diseases causing death and disability worldwide, and the revascularization of damaged tissues is essential for myocardial-injury repair. Circular RNAs (circRNAs) are widely involved in physiological and pathological processes in various systems throughout the body, and the role of circRNAs in cardiovascular disease is gaining attention. In this study, we determined that circERBB2IP is highly expressed in the hearts of newborn mice. Read More

View Article and Full-Text PDF

Prolyl Hydroxylase Domain Protein Inhibitor Not Harboring a 2-Oxoglutarate Scaffold Protects against Hypoxic Stress.

ACS Pharmacol Transl Sci 2022 May 13;5(5):362-372. Epub 2022 Apr 13.

Laboratory of Biochemistry, Department of Applied Biochemistry and Food Science, Faculty of Agriculture, Saga University, 1 Honjo-machi, Saga 840-8502, Japan.

Hypoxia-inducible factor-α (HIF-α) activation has shown promising results in the treatment of ischemia, such as stroke, myocardial infarction, and chronic kidney disease. A number of HIF-α activators have been developed to improve the symptoms of these diseases. Many feature 2-oxoglutarate (2-OG) scaffolds that interact with the active centers of prolyl hydroxylase domain-containing proteins (PHDs), displacing the coenzyme 2-OG. Read More

View Article and Full-Text PDF

Supplementation With Spirulina Reduces Infarct Size and Ameliorates Cardiac Function in a Pig Model of STEMI.

Front Pharmacol 2022 3;13:891801. Epub 2022 May 3.

Cardiovascular Program-ICCC, Research Institute Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain.

Myocardial infarction (MI) is the clinical manifestation of atherosclerotic coronary artery disease. Spirulina is an algae known to ameliorate cardiometabolic disorders and with proven anti-inflammatory and anti-oxidant effects. We investigated, in a highly translatable animal model, whether oral supplementation with spirulina protects against the deleterious effects triggered by ST-elevation MI (STEMI). Read More

View Article and Full-Text PDF

Prognostic Impact of Multiple Lymphocyte-Based Inflammatory Indices in Acute Coronary Syndrome Patients.

Front Cardiovasc Med 2022 3;9:811790. Epub 2022 May 3.

Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Department of Cardiology, Beijing Anzhen Hospital, Clinical Center for Coronary Heart Disease, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China.

Background: The aim of this study was to evaluate the prognostic values of five lymphocyte-based inflammatory indices (platelet-lymphocyte ratio [PLR], neutrophil-lymphocyte ratio [NLR], monocyte-lymphocyte ratio [MLR], systemic immune inflammation index [SII], and system inflammation response index [SIRI]) in patients with acute coronary syndrome (ACS).

Methods: A total of 1,701 ACS patients who underwent percutaneous coronary intervention (PCI) were included in this study and followed up for major adverse cardiovascular events (MACE) including all-cause death, non-fatal ischemic stroke, and non-fatal myocardial infarction. The five indices were stratified by the optimal cutoff value for comparison. Read More

View Article and Full-Text PDF

Troponins in myocardial infarction and injury.

Aust Prescr 2022 Apr 1;45(2):53-57. Epub 2022 Apr 1.

Australian University Medical School, Canberra.

Troponins are proteins that are integral components of the contractile mechanism of muscle, including cardiac muscle. Cardiac troponins Iand T can be detected in the blood of most people after puberty, at concentrations reflecting cardiac mass, sex and age. Current laboratory assays are approximately 1000 times more sensitive than those used previously. Read More

View Article and Full-Text PDF

PRKAR1A and SDCBP Serve as Potential Predictors of Heart Failure Following Acute Myocardial Infarction.

Front Immunol 2022 3;13:878876. Epub 2022 May 3.

Department of Cardiology, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Center for Cardiovascular Translational Research, Peking University People's Hospital, Beijing, China.

Background And Objectives: Early diagnosis of patients with acute myocardial infarction (AMI) who are at a high risk of heart failure (HF) progression remains controversial. This study aimed at identifying new predictive biomarkers of post-AMI HF and at revealing the pathogenesis of HF involving these marker genes.

Methods And Results: A transcriptomic dataset of whole blood cells from AMI patients with HF progression (post-AMI HF, n = 16) and without progression (post-AMI non-HF, n = 16) was analyzed using the weighted gene co-expression network analysis (WGCNA). Read More

View Article and Full-Text PDF